2nd Circ. Affirms Dismissal Of FCA Suit Against Amgen
A whistleblower claiming Amgen Inc. cost the government billions by falsely advertising quality of life benefits for its anemia biologic Epogen failed to actually identify anything that tricked the government into...To view the full article, register now.
Already a subscriber? Click here to view full article